| 注册
首页|期刊导航|中国临床药理学杂志|培美曲塞注射剂联合顺铂注射剂治疗复发性肺腺癌的临床研究

培美曲塞注射剂联合顺铂注射剂治疗复发性肺腺癌的临床研究

陈红 周晓红 陆国权 张缇缇

中国临床药理学杂志2017,Vol.33Issue(12):1079-1081,3.
中国临床药理学杂志2017,Vol.33Issue(12):1079-1081,3.DOI:10.13699/j.cnki.1001-6821.2017.12.002

培美曲塞注射剂联合顺铂注射剂治疗复发性肺腺癌的临床研究

Clinical trial of pemetrexed injection combinded with cisplatin injection in the treatment of recurrent lung adenocarcinoma

陈红 1周晓红 1陆国权 1张缇缇1

作者信息

  • 1. 安顺市人民医院肿瘤科,贵州 安顺561000
  • 折叠

摘要

Abstract

Objective To observe the clinical efficacy and safety of pemetrexed injection combined with cisplatin injection in the treatment of recurrent lung adenocarcinoma.Methods A total of 80 patients with recurrent lung adenocarcinoma were randomly divided into control group (n =40 cases) and treatment group (n =40 cases).Control group was given docetaxel 75 mg · m-2,intravenous infusion for 1 h at day 1 + cisplatin 25 mg · m-2,intravenous infusion for 1 h at day 1-3.Treatment group was given pemetrexed 500 mg · m-2,intravenous infusion at day 1 + cisplatin 25 mg · m-2,intravenous infusion for 1 h at day 1-3.Two groups were treated for 2 cycles with 21 d per cycle.The clinical efficacy,survival time and adverse drug reactions were compared between two groups.Results After treatment,in the treatment and control groups,the overall response rates were 57.50% (23/40 cases) and 47.50% (19/40 cases),the disease control rates were 87.50% (35/40 cases) and 77.50% (31/40 cases)with significant difference (P < 0.05).After treatment,in the treatment and control groups,the median progression-free survival were 6.4 and 5.8 months;the median overall survival time were 9.9 and 9.0 months;1 year survival rates were 35.00% (14/40 cases) and 30.00% (12/40 cases) without significant difference (P > 0.05).The adverse drug reactions in treatment and control groups were based on leukopenia (50.00% vs 47.50%),thrombocytopenia (7.50% vs 10.00%),hemoglobin reduction (37.50% vs 37.50%),nausea and vomiting (52.50% vs 52.50%),hair loss (47.50% vs 47.50%),liver and kidney injury (7.50% vs 7.50%),the differences were not statistically significant (P > 0.05).Conclusion Pemetrexed injection combined with cisplatin injection has a definitive clinical efficacy in the treatment of recurrent lung adenocarcinoma,without increasing the incidence of adverse drug reactions.

关键词

培美曲塞注射剂/顺铂注射剂/复发性肺腺癌/安全性

Key words

pemetrexed injection/cisplatin injection/recurrent lung adenocarcinoma/safety

分类

医药卫生

引用本文复制引用

陈红,周晓红,陆国权,张缇缇..培美曲塞注射剂联合顺铂注射剂治疗复发性肺腺癌的临床研究[J].中国临床药理学杂志,2017,33(12):1079-1081,3.

基金项目

安顺市科技计划基金资助项目[安市科合(2014)07] (2014)

中国临床药理学杂志

OA北大核心CSCDCSTPCD

1001-6821

访问量0
|
下载量0
段落导航相关论文